Free Trial
NASDAQ:CGEN

Compugen (CGEN) Stock Price, News & Analysis

Compugen logo
$1.48 +0.03 (+2.07%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.50 +0.02 (+1.35%)
As of 08/1/2025 06:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Compugen Stock (NASDAQ:CGEN)

Key Stats

Today's Range
$1.35
$1.49
50-Day Range
$1.43
$1.83
52-Week Range
$1.13
$2.66
Volume
282,242 shs
Average Volume
236,550 shs
Market Capitalization
$132.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00
Consensus Rating
Buy

Company Overview

Compugen Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
40th Percentile Overall Score

CGEN MarketRank™: 

Compugen scored higher than 40% of companies evaluated by MarketBeat, and ranked 670th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Compugen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Compugen has received no research coverage in the past 90 days.

  • Read more about Compugen's stock forecast and price target.
  • Earnings Growth

    Earnings for Compugen are expected to decrease in the coming year, from ($0.03) to ($0.12) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Compugen is -9.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Compugen is -9.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Compugen has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Compugen's valuation and earnings.
  • Percentage of Shares Shorted

    1.54% of the outstanding shares of Compugen have been sold short.
  • Short Interest Ratio / Days to Cover

    Compugen has a short interest ratio ("days to cover") of 6.
  • Change versus previous month

    Short interest in Compugen has recently decreased by 7.43%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Compugen does not currently pay a dividend.

  • Dividend Growth

    Compugen does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.54% of the outstanding shares of Compugen have been sold short.
  • Short Interest Ratio / Days to Cover

    Compugen has a short interest ratio ("days to cover") of 6.
  • Change versus previous month

    Short interest in Compugen has recently decreased by 7.43%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Compugen has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Compugen this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Compugen insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.50% of the stock of Compugen is held by insiders.

  • Percentage Held by Institutions

    Only 12.22% of the stock of Compugen is held by institutions.

  • Read more about Compugen's insider trading history.
Receive CGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Compugen and its competitors with MarketBeat's FREE daily newsletter.

CGEN Stock News Headlines

Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.
Compugen First Quarter 2025 Earnings: Misses Expectations
See More Headlines

CGEN Stock Analysis - Frequently Asked Questions

Compugen's stock was trading at $1.53 at the beginning of 2025. Since then, CGEN shares have decreased by 3.3% and is now trading at $1.48.

Compugen Ltd. (NASDAQ:CGEN) announced its earnings results on Monday, May, 19th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.02. The biotechnology company earned $2.28 million during the quarter, compared to the consensus estimate of $3.70 million. Compugen had a negative trailing twelve-month return on equity of 24.51% and a negative net margin of 51.27%.
Read the conference call transcript
.

Compugen's top institutional investors include ARK Investment Management LLC (1.20%), Taylor Frigon Capital Management LLC (1.11%) and R Squared Ltd (0.04%).

Shares of CGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXDW), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), PayPal (PYPL) and

Company Calendar

Last Earnings
5/19/2025
Today
8/01/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CGEN
CIK
1119774
Employees
70
Year Founded
1993

Price Target and Rating

High Price Target
$4.00
Low Price Target
$4.00
Potential Upside/Downside
+171.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.16)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$14.23 million
Net Margins
-51.27%
Pretax Margin
-34.78%
Return on Equity
-24.51%
Return on Assets
-12.19%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.09
Quick Ratio
5.09

Sales & Book Value

Annual Sales
$27.59 million
Price / Sales
4.77
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.62 per share
Price / Book
2.38

Miscellaneous

Outstanding Shares
89,237,000
Free Float
80,759,000
Market Cap
$131.62 million
Optionable
Optionable
Beta
2.57

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:CGEN) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners